Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
120,020,745
-
Total 13F shares
-
28,795,595
-
Share change
-
+5,683,688
-
Total reported value
-
$29,946,056
-
Price per share
-
$1.04
-
Number of holders
-
58
-
Value change
-
+$5,248,294
-
Number of buys
-
21
-
Number of sells
-
32
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q1 2020
As of 31 Mar 2020 Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) had 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 28,795,595 shares of stock of the company.
Largest 10 holders included MFN Partners Management, LP, RENAISSANCE TECHNOLOGIES LLC, Endurant Capital Management LP, Samsara BioCapital, LLC, EcoR1 Capital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Sofinnova Investments, Inc., Vivo Capital, LLC, Rock Springs Capital Management LP, and Parkman Healthcare Partners LLC.
This table shows 59 institutional shareholders of the security as of 31 Mar 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.